2022 - 2023
RUTGERS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

In partnership with
MERCK
Rutgers Institute for Pharmaceutical Industry Fellowships
# TABLE OF CONTENTS

- A Message from Leadership ........................................................................................................... 3
- About Merck .................................................................................................................................. 4
- Leadership Team ............................................................................................................................ 9

**Merck Research Laboratories (MRL) Fellowships**

- Clinical Safety & Risk Management ................................................................................................ 11
- Late Stage Clinical Development ...................................................................................................... 12
- Global Regulatory Affairs ................................................................................................................. 14
- Regulatory Affairs International ........................................................................................................ 15
- Regulatory Affairs Advertising and Promotion .................................................................................. 16
- Translational Medicine ..................................................................................................................... 17
- Global Medical Affairs—Oncology ..................................................................................................... 18
- Global Medical Information ............................................................................................................... 19
- Global Scientific Content ................................................................................................................... 20
- Global Field Medical Center of Excellence ....................................................................................... 21
- US Medical Affairs ............................................................................................................................ 22

**Human Health (HH) Fellowship**

- US Oncology Marketing ................................................................................................................... 23
- Global Vaccines Marketing ............................................................................................................... 24

**Alumni Spotlight** .......................................................................................................................... 25

**Rutgers Component** ....................................................................................................................... 28
A MESSAGE FROM LEADERSHIP

On behalf of Merck & Co., and the Ernest Mario School of Pharmacy at Rutgers University, thank you for expressing your interest in the Pharmaceutical Industry Fellowship Program. As you move forward in your career, I encourage you to consider the fellowship opportunities at Merck.

Led by former fellows and senior members of the management team, Merck Research Laboratories (MRL) has designed two-year fellowship programs that will offer you a tremendous opportunity to learn, grow, and be part of a dynamic and exciting culture in the areas of Translational Medicine, Clinical Sciences and Study Management, Clinical Safety & Risk Management, Global Regulatory Affairs, Global Medical Affairs, and Global Medical Information. In addition, Merck has expanded its fellowship program into its Health Human (HH) division and offers a US Oncology Marketing fellowship. We believe these critical areas in the drug development process and commercial organization offer fellows a unique opportunity to build skills and gain hands on experience that will be invaluable as they pursue a rewarding career in the pharmaceutical industry.

We have a strong commitment to continually develop a program that can generate success for you, Rutgers University, and Merck. We recognize that you are among the best and the brightest coming out of pharmacy school, bringing a strong track record of high achievement. Our program is designed to allow you to continue your success in a post-doctoral environment and for us to work with and train the potential leaders of tomorrow.

The fellowship program at Merck is occurring at an exciting time as we have the most powerful R&D engine in our company’s history. Merck is a strong and diverse company with an extensive global reach. We have a broad pipeline, a number of products to help people, and we are more passionate than ever about what matters most to our customers and the patients we serve.

At Merck, we see every employee as both a team member and a potential leader with the power to influence others through his or her actions. Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity, and teamwork of our employees. This fellowship program is a component of our organizational focus on people.

As many of you will learn from the Merck fellowship leadership team during your interviews, we all take great pride in our work and our business of improving human health. We have an excellent program, and we’re looking for exceptional candidates to become a part of that program. I wish you the best of luck during the recruitment process and hope you will strongly consider the unique fellowship opportunities at Merck.

With Best Regards,

Roy D. Baynes, M.D., Ph.D.
Chief Medical Officer, Senior Vice President
Global Clinical Development
Merck Research Laboratories

MERCK
INVENTING FOR LIFE
OUR VALUES

PATIENTS
We are all accountable for delivering high quality products and services. We aspire to improve the health and wellness of people and animals worldwide and to expand access to our medicines and vaccines. All of our actions must be measured against our responsibility to those who use or need our products.

RESPECT FOR PEOPLE
Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity, safety and teamwork of our employees. To this end, we work to create an environment of mutual respect, inclusion and accountability. We reward commitment and performance and are responsive to the needs of our employees and their families.

ETHICS AND INTEGRITY
We are committed to the highest standards of ethics and integrity. We are responsible to our customers, to our competitors, to distributors and suppliers, to shareholders and to the communities we serve worldwide. In discharging our responsibilities, we do not take professional or ethical shortcuts. Our interactions with all segments of society must be transparent and reflect these high standards.

INNOVATION AND SCIENTIFIC EXCELLENCE
We are dedicated to innovation and scientific excellence. Our research is guided by a commitment to improving health and the quality of life. We strive to identify the most critical needs of patients and customers, and through continuous innovation we challenge ourselves to meet those needs.

“We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.”

George W. Merck, Merck President and Chairman 1925-1957
AT MERCK, WE ASPIRE TO SOLVE THE WORLD’S CHALLENGES TO HEALTH AND WELL-BEING TO ENSURE THE CONTINUITY OF HUMAN PROGRESS

<table>
<thead>
<tr>
<th>WHAT WE DO</th>
<th>HOW WE DO IT</th>
<th>WHY IT MATTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENABLE GENERATIONS</td>
<td>BRAVE INVENTION</td>
<td>ADVANCE SOCIETY</td>
</tr>
</tbody>
</table>

**1891**
Leaving Darmstadt, Germany, George Merck arrives in New York and establishes Merck & Co, Inc.

**1899**
The first Merck Manual was published in 1899 and went on to become one of the most widely used medical references.

**1933**
The founder’s son, George W. Merck, launches major new research laboratories in Rahway, New Jersey, soon leading to breakthroughs in vitamins, antibiotics, and anesthetics.

**1942**
Merck’s penicillin “G” is used in the first successful treatment of blood infection with penicillin in the U.S. Ramping up production for the war earns Merck the Army-Navy “E” Award for excellence in manufacturing.

**1943**
Dr. Selman Waksman and Albert Schatz discovered streptomycin, the first effective treatment for tuberculosis. Merck had supported Dr. Waksman’s research lab and held the new drug’s patent rights. Once its significant health benefits were recognized, Merck relinquished its exclusive patent on the antibiotic to ensure maximum patient access.

**1953**
The merger with Sharp & Dohme brings to Merck important new expertise in biological and vaccine research and global distribution.

**1966**
Following a decade of intensive research, Merck’s protease inhibitor is approved for treating HIV in just 45 days, one of the fastest FDA reviews to date.

**1971**
Measles, mumps, and rubella virus vaccine is launched in an innovative combined form.

**1986**
Recombinant hepatitis B vaccine is launched – the first genetically engineered vaccine approved for humans, and the first to prevent cancer.

**1987**
Ivermectin is developed for river blindness and distributed free to all who need it. As of 1987, the company has donated 2.5 million tablets (estimated value of $3.75 billion).

**1996**
SERVEBO becomes the first FDA-approved vaccine for prevention of disease caused by the Ebola Zaire virus for adults.

**2006**
The first DPP-4 inhibitor for type 2 diabetes is approved by the FDA.

**2006**
The first vaccine to prevent cervical cancer (the fourth most common cancer in women).

**2009**
The company and Schering-Plough merge to create a stronger, more diverse global healthcare company.

**2011**
The company launches the 10-year Merck for Mothers initiative, a global effort to bring the issue of maternal mortality to the forefront of global consciousness.

**2014**
Helping people fight cancer is our passion. The first anti-PD-1 for the treatment of advanced melanoma receives approval for use in the U.S.

**2015**
The Nobel Prize in Medicine is awarded to Dr. William Campbell, one of the scientists who discovered avermectin, which later led to the creation of ivermectin, the key component of the company’s revolutionary anti-river blindness drug.

**2019**
Merck remains dedicated to solving global health challenges. ERVEBO becomes the first FDA-approved vaccine for prevention of disease caused by the Ebola virus for adults.
OUR KEY INITIATIVES

MERCK FOR MOTHERS

Our 10-year, $500 million initiative applies our scientific and business expertise to reduce maternal deaths worldwide.

Over 13.1 million women have been reached through programs promoting safe, high-quality, and respectful care. There have been 78 million people reached through improved access to quality facilities.

OUR COMMITMENT TO END RIVER BLINDNESS

More than 25 years ago, we committed to donate our medicine, Ivermectin — as much as needed, for as long as needed — with the goal to help eliminate river blindness in affected areas in Africa, Latin America and Yemen. In 2019, $3.10 million dollars were donated to the program and 403 million treatments were approved.

River blindness is now eliminated in Colombia, Ecuador, Guatemala, and Mexico.

Merck Medical Outreach Program

The Merck Medical Outreach Program (MMOP) was established over 60 years ago to help provide lifesaving medicines and vaccines to those in need.

The MMOP is the primary means through which the company donates its pharmaceuticals and vaccines for humanitarian assistance in the developing world and in support of disaster relief worldwide.

MERCK FELLOWSHIP FOR GLOBAL HEALTH

Our corporate pro bono program connects our employees with non-governmental organizations worldwide to help increase access to health services and to education in local communities.

220 RTC fellows between 2012 and 2019 from 37 different countries worked with 34 non-governmental organizations.
CURRENT PROMOTED PRODUCTS
MERCK PROGRAM
LEADERSHIP

EXECUTIVE SPONSORS

Eric Rubin, MD
Executive Sponsor
Senior Vice President
Clinical Research Oncology
Early Development

Jill DeSimone, B.S. Pharm
Executive Sponsor
Senior Vice President
US Oncology Commercial Operations

Eliav Barr, MD
Executive Sponsor
Senior Vice President
Global Medical Affairs

Dean Y. Li, MD, PhD
Executive Sponsor
President of Merck Research Labs

LEADERSHIP TEAM

Sauzanne Khalilieh, PharmD
Fellowship Director
Program Alumna
Executive Director
Translational Medicine

Ripal Shah, PharmD
Fellowship Director
Program Alumna
Director
Worldwide Regulatory Group

Gowri Murthy, PharmD, MBA
Professional Development Lead
Program Alumna
Senior Principal Scientist
Genomics Policy

Anne Flanigan-Minnick, PhD
Medical Affairs Fellowship Lead
Executive Director
Global Medical Information
Global Medical Affairs

Adam Saluccio, PharmD
Chief Fellow
Clinical Safety and Risk Management

Megan Larison, PharmD
Chief Fellow
Global Medical Affairs — Oncology
MERCK FELLOWSHIPS

- Clinical Safety & Risk Management
- Late Stage Clinical Development
- Global Regulatory Affairs*
- Regulatory Affairs International
- Regulatory Affairs Advertising and Promotion
- Translational Medicine
- Global Medical Affairs—Oncology
- Global Medical Information
- Global Scientific Content
- Global Field Medical Center of Excellence
- U.S. Medical Affairs*
- U.S. Oncology Marketing
- Global Vaccines Marketing

*Not recruiting for 2022-2023
Within Global Regulatory Affairs and Clinical Safety (GRACS), the Clinical Safety & Risk Management (CSRM) department’s mission is to improve public health by assuring the safe use of Merck products worldwide through proactive safety assessment, effective risk management, and transparent risk communication throughout the developmental and marketed product life-cycle.

The goal of the CSRM fellowship is to prepare the fellow for a career in pharmacovigilance and risk management in the pharmaceutical industry. This will be done through a rigorous, hands-on training program that exposes the fellow to the various aspects of global product safety in an industry setting.

Under the general direction and mentoring of a CSRM Director, the fellow will develop expertise in, and gradually assume greater responsibility for, the overall clinical risk management and safety surveillance of assigned marketed products. The fellow will learn about all aspects of safety surveillance, including assessing safety information, safety signaling, along with ensuring completeness of that safety information in worldwide package circulars. The fellow will have joint responsibility for the development of periodic safety update reports and risk management plans and will partner with appropriate Merck departments and therapeutic areas to ensure efforts are aligned to meet our global risk management strategies for assigned products. The fellowship will also involve working with the CSRM group to help develop processes for the improved functioning of the fellowship program, and implement specific initiatives to achieve identified goals.

The fellow will have the opportunity to interact with other departments within Merck, such as Medical Affairs, Epidemiology, Clinical Research, Biostatistics, and Regulatory Affairs to learn how Clinical Safety & Risk Management is incorporated throughout the organization. Additionally, the fellow will learn how pharmaceutical manufacturers use data to support research, development, approval, and access for new therapeutic products.

Recruiting: 1 Fellow
Global Clinical Trial Operations (GCTO) supports Merck’s Mission to discover, develop, and provide innovative products and services that save and improve lives around the world. Clinical Sciences & Study Management (CSSM) is a subfunctional unit within GCTO accountable for all operational, technical, and scientific aspects of headquarters-sponsored clinical trials, including local registration trials and regulatory commitments. The Clinical Scientist (CS)/Study Manager (SM) fellows will support the scientific aspects of late stage clinical development within therapeutic areas of oncology, ID/vaccines, or general medicine, as well as play a key role in the operational planning and execution activities for our late stage development clinical studies around the globe.

Through involvement and interaction with other functional areas, the fellow will become familiar with protocol design, scientific and operational oversight of trials, reporting trial results, and more. The fellow will serve as a core member of a Clinical Trial Team (CTT) and collaborate with other functional areas including Clinical Directors, Statistics, Regulatory Affairs, Therapeutic Area Document Review Committees, Data Management, Clinical Supplies, and Regional Clinical Operations. The principle goals of the fellowship will be to provide an overview of the functional role of the CS/SM in the drug development process, and training opportunities aligned with the role of the CS/SM at Merck.

(continued on next page)
The fellow will have the opportunity to be involved with study start-up, conduct, closeout, and potentially registration activities.

Responsibilities may include:

- Study planning and management
- CTT leadership
- Protocol/amendment authoring
- Case report form development
- Budget management
- Protocol feasibility
- Country selection
- Patient enrollment projections
- Medical monitoring of clinical data
- Trial tracking and reporting
- Program and study communication
- Clinical study reports and/or publication authoring.

Overall, the fellow will have the chance to help advance Merck’s pipeline of innovative drug candidates so that they might benefit people around the world.

Recruiting: 5 Fellows (3 Oncology, 1 General Medicine, 1 ID/Vaccine)
GRACS REGULATORY FELLOWSHIPS
The goal of the regulatory fellowships in Global Regulatory Affairs and Clinical Safety (GRACS) at Merck is to prepare the fellow for a career in regulatory affairs in the pharmaceutical industry. This will be done through a rigorous, hands-on training program that exposes the fellow to a variety of functional areas where they will support key strategic regulatory milestones.

There are two different regulatory fellowships in GRACS: Global Regulatory Affairs (GRA) and Regulatory Affairs International (RAI). While both positions have a focus on regulatory strategy and providing regulatory intelligence, the two positions differ in responsibilities and geographic focus.

Global Regulatory Affairs (GRA)
Key Therapeutic Area Liaison (TAL) Responsibilities:

- Serve as the global regulatory strategy lead for assigned programs proactively provide regulatory expertise and strategic guidance in all aspects of the drug development process.
- Provide global regulatory strategic input in the design of preclinical and clinical development programs for all Merck pharmaceutical products, with a focus on the US, Canada, China, and Japan.
- Lead the development of initial and supplemental world marketing applications and global filing strategies, contribute to the creation and maintenance of the company core data sheet (CCDS), and participate in launch and post filing activities.
- Oversee health authority (HA) meetings, particularly in the US, and support HA requests, such as Agency inquiries, preparation of Agency background packages, and drug development plans.
- Ensure that the content, organization, and quality of all regulatory documentation follows regulatory requirements and commitments.

GRA Fellowship Opportunities:

- Be a member of cross-functional project teams and gain experience in the development of global regulatory strategic plans, filing and/or strategic development of regulatory dossiers, and routine and complex requests from HA.
- Provide regulatory intelligence and lead regulatory aspects of development milestones.
- Explore opportunities in industry-specific experiences and topics, such as external collaborations, innovative company projects and policy development.
- Gain experience in the global regulatory strategic plans, especially in the US.
- Interact with other departments at Merck, such as Clinical Research, Chemistry, Manufacturing and Controls (CMC), and Clinical Safety and Risk Management (CSRM).
- Take part in the filing and strategic development of regulatory dossiers.

*NOT RECRUITING FOR 2022-2023
Regulatory Affairs International (RAI) – Oncology

Key RAI Liaison Responsibilities:

- Provide regulatory oversight for development/approval of Clinical Trial Applications (CTA) for oncology indication in countries outside the US and use clinical outcome to build regulatory strategy with a high focus on access.
- Facilitate responses to Health Authority questions and lead the Response to Query (RTQ) process outside of the US.
- Support the clinical development programs in Phase I-IV, with a focus on Most-of-World (MOW). MOW represents Latin America, Asia Pacific, Eastern European, Middle East, and African countries.
- Provide MOW regulatory expertise, country specific regulatory knowledge and an understanding of the changing regulatory landscape within these countries.
- Support strategic registrational activities, including the development of filing strategies, in MOW countries as part of a broader team.
- Advocate for consideration of MOW requirements in development programs.
- Ensure that the content, organization, and quality of all regulatory documentation follows regulatory requirements and commitments.

RAI Fellowship Opportunities:

- Explore opportunities in industry-specific experiences and topics, such as external collaborations, innovative company projects and policy development.
- Gain experience in the global regulatory strategic plans in MOW countries.
- Exposure to regulatory projects involving the US FDA under guidance of Merck subject matter experts.
- Interact with other departments at Merck, such as Clinical Research, Chemistry, Manufacturing and Controls (CMC), and Clinical Safety and Risk Management (CSRM).
- Take part in the filing and strategic development of regulatory dossiers.

Recruiting: 1 Fellow

Cathy Hoath
Director, Regulatory Affairs International
PRECEPTOR

Abou Bakar, PharmD
First Year Fellow
As part of Merck’s Global Regulatory Affairs and Clinical Safety (GRACS) group, Regulatory Affairs proactively provides regulatory expertise and strategic guidance in all aspects of the drug development process in order to ensure the production of quality submissions that meet Health Authority requirements and allow for expeditious review and approvals.

Regulatory Affairs is also responsible for maintaining marketed products in compliance with FDA’s regulatory requirements. The focus of this two-year fellowship is in the Office of Promotion and Advertising Review (OPAR) group within GRACS. This group is responsible for ensuring advertising and promotional materials are compliant and accurately reflect the unique characteristics which differentiate our products and our company in the marketplace.

During this 2-year fellowship, the fellow will:

- Develop an understanding of the federal laws, regulations, and guidances that guide the promotion of prescription drugs and biologics for both healthcare professionals and consumers
- Analyze Office of Prescription Drug Promotion (OPDP) enforcement letters to assess the impact on current promotional activities within the industry
- Understand the Promotion Review Team (PRT) and Digital Engagement Team (DET) processes at Merck to review internal promotional trainings and external promotional materials
- Collaborate with a variety of functional areas (marketing, legal, and medical) to ensure promotional activities are aligned with federal regulations and Merck corporate policies
- Assist in identifying and mitigating regulatory risks within promotional materials to support the business

In addition to the focus on promotion, the fellow will be provided with exposure to other departments within GRACS, such as Regulatory Labeling and Worldwide Regulatory Group, to appreciate the role of GRACS in prescription drug and biologic development and maintenance.

The goal of the OPAR fellowship is to prepare the fellow for a career in advertising and promotion regulatory affairs in the pharmaceutical industry through a rigorous, hands-on training program in an industry setting.

Recruiting: 1 Fellow
Within the Discovery, Preclinical & Translational Medicine (DPTM) department, the Translational Medicine (TMed) group is responsible for the conduct of clinical trials. TMed conducts the clinical evaluation of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of molecular and biological therapeutics in healthy and patient populations within the regulatory requirements for new investigational products. The TMed group includes the following divisions: TMed Therapeutic Areas, TMed Operations (TMed Ops) and EU Operations.

The TMed Therapeutic Areas are aligned with the Discovery Organization and include Cardiovascular and Metabolic Diseases, Neurology, Oncology, and Infectious Disease/Vaccines/Inflammation. The mission of this group is to discover new targets and biomarkers based on causal human biology, design and conduct first in human (FIH) and clinical proof of concept (PoC) studies, and build novel clinical platforms to test therapeutic hypothesis. TMed conducts trials to evaluate clinical pharmacology and support programs across the entire life cycle of a product from FIH, through the development of novel post-market formulations. TMed Ops provides efficient operational support for all clinical trials within DPTM, and the EU Operations group conducts non-US trials to advance compounds and establish safety and clinical PoC. Collectively, TMed provides all the preliminary safety, PK, and PD scientific support for the progression into late stage clinical studies in patients across all Merck Research Laboratories therapeutic areas.

Within TMed Ops, the Early Clinical Scientist fellow will be a member of the Study Team and responsible for:

- Collaborating with other functional area representatives including Pharmacokinetics and Drug Metabolism, Statistics, Data Management, Clinical Supplies, and Regulatory Affairs
- Initiating studies that are geared toward the understanding of new molecular entity safety and tolerability in healthy subjects and patients, mechanism of action, PK, drug-drug interactions, PD, as well as PoC
- Developing trial protocols and case report forms for data collection
- Participating in data monitoring and the clean-up of databases at the end of studies
- Leading Clinical Study Report authoring at the completion of studies

**Recruiting: 1 Fellow**
Global Medical Affairs (GMA), which is part of Merck Research Laboratories (MRL), plays a critically important role in communicating about our scientific program and advancing patient care. We engage in peer-to-peer, bi-directional scientific exchange with external stakeholders to improve understanding of our company’s innovative pipeline and licensed products. These exchanges also yield valuable insights, which we share with our internal partners in Global Clinical Development, Human Health and the Center for Observational and Real-World Evidence to help inform decision making regarding product development, commercialization, and life-cycle management activities.

This 2-year fellowship provides a unique opportunity to focus in the oncology therapeutic area, one of the most exciting areas of pharmaceutical research and development. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through collaborative leadership experiences in areas including Global Medical Information (GMI), Global Scientific Content and Training, Global & U.S. Medical Strategy, and Field Medical.

GMA Oncology Fellows will expand their knowledge by gaining exposure to a wide range of oncology therapeutic areas including thoracic, gastrointestinal, genitourinary, hematologic, lung, melanoma, head & neck and women’s cancers.

First Year Opportunities and Responsibilities:
- Work primarily in GMI on the Oncology Therapeutic Area Teams
- Gain solid foundational knowledge of assigned products and tumor types
- Become familiar with responding to unsolicited Medical Information Requests (MIRs) and learn how fair, balanced, and accurate responses are developed and sent to customers
- Gain experience in the medical review of promotional materials and scientific content for marketed products, while learning how training materials are developed/delivered
- Assist with Compendia and Pathways submissions
- Become involved in worldwide launch activities

Second Year Opportunities and Responsibilities:
- Rotate through multiple functional areas within Medical Affairs per business need and personal interest. Rotational opportunities include but are not limited to: Global Scientific Content and Training, Global & U.S. Medical Strategy, Global Operations, Field Medical, and Health Systems Oncology
- Focus on scientific leader engagements, collaborate with stakeholders within the U.S. and around the world to develop a medical strategy plan, and proactively create resources to support the field’s scientific exchange with scientific leaders

Recruiting: 2 Fellows
Global Medical Information (GMI) is a critical part of Global Medical Affairs (GMA) at Merck. GMA serves as a strategic partner, providing high quality medical expertise to the business and to our external customers. GMA helps to meet the needs of healthcare professionals and organizations by generating resources and communicating information that helps them make informed choices that improve health outcomes for patients.

GMI includes a diverse group of scientists and healthcare professionals with a mission to:

- Review and approve medical/scientific content that is leveraged by Field Medical and local Medical Information colleagues to provide accurate and timely medical information to unsolicited requests from healthcare professionals, hospitals, and managed care organizations
- Provide medically accurate review/approval of US and Global advertising and promotional materials created by marketing/promotion, training, and managed care
- Develop and deliver medical assets for product and disease training
- Submit summaries of groundbreaking data to Compendia organizations to expand patient access to our medicines and to support evidence-based decision making by healthcare professionals
- Support launch activities around the globe

GMI interacts cross-functionally and collaboratively with many departments, including the Office of Promotion & Advertising Review, Regulatory Affairs, Learning and Development, Global Safety, Clinical Research, Center for Outcomes and Real-World Evidence, Legal, Compliance, Global Quality, Merck Manufacturing Division, and US and Global Marketing.

During this two-year fellowship in GMI, fellows will work in one or more key therapeutic areas. Fellows will become familiar with responding to unsolicited Medical Information Requests (MIRs) and learn how fair-balanced and accurate responses are developed and sent to customers. They will gain experience in the medical review of promotional materials and scientific content for marketed/investigational products, learn how training materials are developed/delivered, and become involved in worldwide launch activities.

The Fellow in this Merck Rutgers program will receive broad experience and exposure across the GMA organization, and beyond.

Recruiting: 1 Fellow
Global Scientific Content (GSC) is a part of Global Medical and Scientific Affairs (GMSA) and includes a diverse group of scientists and healthcare professionals. GSC focuses on the strategic planning, development, and management of scientific content used by Global Medical Information (GMI) and Field Medical to facilitate scientific exchange and respond to unsolicited medical information requests from healthcare professionals, hospitals, and managed care organization. The mission of GSC is to provide world-class scientific content for use at the global and regional levels.

The fellow will have the opportunity to support various indications and therapeutic agents by performing the following responsibilities:

- Author and work with external vendors to develop scientific content, including medical information letters (MILs), verbal response documents (VRDs), slide decks, and digital/web-based medical content.
- Engage key departments, such as Global/Regional Medical Strategy, Field Medical, and Legal, in the review of scientific content to ensure cross-functional alignment on scientific content under development.
- Support and participate in congress and launch activities by preparing/sharing scientific content plans and developing content based on the needs of the cross-functional medical team.
- Contribute to key scientific content-related training initiatives as needed.

The first year of the fellowship will consist of two 6-month rotations in the GSC oncology and ID/vaccines teams.

The second year will be rotational depending on the fellow’s interests and the company’s needs. There is opportunity for fellows to rotate across the company, including but not limited to the following departments:

- The Field Medical Center of Excellence (GST)
- Global Medical Information (GMI)
- Medical Strategy
- Publications
- Global Expert Input and Medical Education (GEIMed)

Recruiting: 1 Fellow
The Global Field Medical Center of Excellence (FM CoE) is a function within Global Medical & Scientific Affairs (GMSA) that is responsible for creating tools, training and/or processes to strengthen the Field Medical capability of Merck worldwide. Within the FM CoE resides three functions which include: Global Scientific Training (GST), Global Field Medical Excellence, and Core Skills and Capabilities. The Fellow’s primary role will be in GST, working in either ID/Vaccines or Oncology, two therapeutic areas that are rapidly expanding across the industry.

Responsibilities may include:

- Working cross functionally with members of the Global Medical Affairs Team to develop and execute the Global Scientific Training plan in their respective therapeutic area for our Field Medical professionals.
- Supporting execution of the GST plan. This includes developing and delivering the training to field medical professionals around the world via webinars, workshops, train-the-trainer sessions, or the medical academy.
- Engaging globally through partnership with Medical Affairs professionals across Merck’s affiliates around the world.

The fellow will gain skills and experience in:

- Their respective therapeutic area, while working cross-functionally with members of the Global Medical Affairs team. The cross collaboration required for such implementation will expose each fellow to a variety of stakeholders and help them develop a robust network within Merck.
- Communications between Global Strategy, Content and Field Medical Leadership which will foster a unique understanding of various focal points within the pharmaceutical industry.
- Understanding the policies and procedures related to training to ensure the fellows understands how to work compliantly.

**FM CoE Rotational Opportunities:** In addition to their primary responsibilities, the fellow will have the opportunity to rotate, or take on projects within the other functions in the FM CoE, including Core Skills and Capabilities and Field Medical Excellence.

The FM CoE looks forward to welcoming these fellows into a dynamic, global role where they will gain skills that will be foundational to a career in the pharmaceutical industry.

**Recruiting:** 1 Fellow
US Medical Affairs (USMA) is a credible and trusted partner to internal and external stakeholders, conducting high-quality, peer-level scientific exchange and research discussions with scientific leaders, investigators and key decision makers to advance clinical practice and bring benefit to patients. USMA fellows will have experiences across a range of therapeutic areas, including cardiovascular and metabolic disease, neuroscience, virology, infectious disease, oncology, and anesthesia/surgery, as well as gain experience working with Health Systems. They also will rotate through the following functions in the GMAC (Global Medical Affairs Capabilities) organization and in support of:

**Field Medical Function:** Field Medical colleagues Regional Medical Scientific Directors (RMSDs), and Health Systems Medical Affairs Directors (HS MADs) are therapeutic area and disease experts, who engage in scientific exchange with the external medical and scientific community. RMSDs focus on specific therapeutic areas, engaging with a range of scientific leaders, while HS MADs provide cross-therapeutic support to decision makers within payer and provider organizations across the country. The fellow will have the opportunity during the field medical rotation to interact with Field Medical colleagues and observe scientific and medical discussions between Field Medical personnel and members of the healthcare community.

**Medical Affairs Therapeutic Areas:** The Scientific Directors of Medical Affairs (SDMAs) and Regional Directors of Medical Affairs (RDMAs) provide expert scientific and medical leadership to Merck for each therapeutic area to support the development of appropriate medical affairs strategies. SDMAs and RDMAs maintain relationships with internal stakeholders to ensure strategic alignment of medical affairs activities. SDMAs and RDMAs also engage with external stakeholders to obtain input that may inform the Medical Affairs strategy. During the strategy rotation, the fellow will work closely with SDMAs and RDMAs to participate in the input gathering and strategic decision-making process.

**Global Scientific Content (GSC):** GSC colleagues work to provide Field Medical colleagues with approved resources for medical and scientific training and for use in scientific exchange with scientific leaders and key decision makers. In the content rotation, the fellow will work under the guidance of GSC colleagues to help drive the process of global medical and scientific content development, review and approval.

**Operations:** The Operations team is staffed by Project Managers who work across functional areas within Merck to drive the new and existing initiatives aligned to the USMA strategies. Operations is responsible for meeting management, communications, systems, reporting and business analytics, training, and other key operational responsibilities. The fellow will have the opportunity to execute cross-functional projects designed to help achieve USMA organizational objectives.

**Global Professional Relations and Independent Medical Education (GPRIME):** GPRIME managers establish and maintain high quality relationships with professional societies to support educational efforts. The GPRIME team is engaged in interactions with the leadership of numerous patient advocacy groups, and professional medical and pharmacy societies to drive independent accredited medical education. Through the GPRIME rotation, the fellow will understand the independent accredited education of health professionals and learn about organizational relationships.

*NOT RECRUITING FOR 2022-2023*
Merck’s Oncology team is dedicated to delivering breakthrough innovations that extend and improve the lives of cancer patients worldwide. This team of forward-thinking individuals achieve this goal through an unwavering commitment to support accessibility to medicine, providing new therapeutic solutions, and collaborating with governments and payers to ensure that people who need medicines have access to them. The focus on innovation and launch execution excellence allows us to translate breakthrough science into innovative medicines that help people with cancer across the globe.

The US Oncology Marketing Fellowship will be a part of Merck’s Human Health US commercial marketing organization as part of a marketing team solving complex business challenges to improve product offerings as well using business analytics to identify insights, assess opportunities, and drive solutions.

The goal of the US Oncology strategic marketing fellowship is to prepare the fellow for a career in strategic pharmaceutical marketing, market access, market research, marketing communications, or regulatory promotions.

The Marketing Fellow will be part of a team driving strategy and growth and support the development of strategic marketing resources and programs for assigned indication(s). Responsibilities may include:

- Strategic development of HCP and medical education resources
- Digital promotion, including working with external agencies in execution and management
- Brand management and launch planning
- Communications planning and management
- Supporting the review of promotional materials working in partnership with marketing colleagues, and our legal, regulatory, medical and compliance teams
- Working across functional areas including field sales, training, compliance, legal, digital/consumer marketing, access and reimbursement; and market research

The fellowship will provide hands-on experience solving complex problems; researching and addressing internal/external challenges and customer needs to improve product marketing offerings; as well as financial planning and management activities such as budget management, forecasting, and business case development.

Recruiting: 1 Fellow
Merck Global Vaccines is dedicated to helping protect current and future generations from preventable infectious diseases. This is aligned with our company mission to discover and develop innovative medicines & vaccines that save and improve lives around the world. We are an engaged, diverse team of professionals building on Merck’s 130-year legacy as a global leader and innovator of vaccines for both infants and adults.

The Global Vaccines Marketing Fellowship is part of Merck’s Human Health Global Marketing Commercial organization, with direct alignment to the Global Pneumococcal Vaccines franchise marketing team. The Pneumococcal Vaccines team is responsible for global marketing of an inline vaccine as well as a number of innovative pipeline of pneumococcal vaccine candidates.

The goal of the Global Vaccines Marketing Fellowship is to prepare the fellow for a career in strategic pharmaceutical marketing, commercial strategy, marketing communication, market research and general management. The fellow will contribute to our global commercial portfolio and asset strategy, product pricing, product allocation, new product launch planning, country engagement and cross-functional matrix team collaboration. Responsibilities may include:

- Scientific strategy and content development
- Brand management and launch planning
- Global marketing launch planning and market development
- International country marketing team engagement
- Project ownership, Agile project management training and leadership
- Working with enterprise cross-functional colleagues, including Investor Relations, Media & Communications, Medical Affairs, Health Outcomes, Market Access, Clinical, Regulatory and Manufacturing

This exciting fellowship offers hands-on experience in global marketing, commercial strategy, communication and problem solving, with an opportunity to gain insight into financial forecasting and budgeting, strategic planning, customer insights, promotional marketing and scientific communication.

Recruiting: 1 Fellow
<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
<th>Class Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Kam, PharmD</td>
<td>Director, Oncology Global Medical Affairs</td>
<td>2018</td>
</tr>
<tr>
<td>Abiola Ojo, PharmD</td>
<td>Director, Oncology Global Medical Affairs</td>
<td>2019</td>
</tr>
<tr>
<td>Anna Yang, PharmD</td>
<td>Director, Oncology Global Medical Affairs</td>
<td>2019</td>
</tr>
<tr>
<td>Laura Buckley, PharmD</td>
<td>Associate Director, Oncology Global Scientific Content</td>
<td>2019</td>
</tr>
<tr>
<td>Nadia Noormohamed, PharmD</td>
<td>Senior Scientist, QP2</td>
<td>2019</td>
</tr>
<tr>
<td>Tyler Stone, PharmD</td>
<td>Senior Specialist, Global Medical Information</td>
<td>2020</td>
</tr>
<tr>
<td>Michelle Chawla, PharmD</td>
<td>Senior Scientist, Late Stage Clinical Development</td>
<td>2020</td>
</tr>
<tr>
<td>Lav Patel, PharmD</td>
<td>Senior Specialist, Office of Promotion &amp; Advertising Review</td>
<td>2020</td>
</tr>
<tr>
<td>Punam Patel, PharmD</td>
<td>Associate Director, Oncology Global Medical Strategy</td>
<td>2020</td>
</tr>
<tr>
<td>James Young, PharmD</td>
<td>Associate Director, Late Stage Clinical Development</td>
<td>2020</td>
</tr>
</tbody>
</table>
Liz Paschka, PharmD  
Senior Scientist, Clinical Safety & Risk Management  
Clinical Safety & Risk Management, Merck, Class of 2020

Marc Fares, PharmD  
Associate Director, Field Medical Center of Excellence  
US Medical Affairs, Merck, Class of 2020

Andy Xu, PharmD  
Senior Scientist, Late Stage Clinical Development  
Translational Medicine, Merck, Class of 2021

Samuel Kwarteng, PharmD  
Senior Scientist, Clinical Safety & Risk Management  
Clinical Safety & Risk Management, Merck, Class of 2021

Jacob Pyrzynski, PharmD  
Senior Scientist, Late Stage Clinical Development  
Late Stage Clinical Development, Merck, Class of 2021

Mary-Gwen Miller, PharmD  
Senior Scientist, Late Stage Clinical Development  
Late Stage Clinical Development, Merck, Class of 2021

Wyatt Chafin, PharmD  
Senior Scientist, Late Stage Clinical Development  
Late Stage Clinical Development, Merck, Class of 2021

Angela Lee, PharmD  
Senior Scientist, Regulatory Affairs International  
Regulatory Affairs International, Merck, Class of 2021

Mark Hanna, PharmD  
Senior Scientist, Regulatory Affairs International  
Regulatory Affairs International, Merck, Class of 2021

Janki Patel, PharmD  
Senior Specialist, Global Medical Information  
Global Medical Information, Merck, Class of 2021

Olivia Vanscoy, PharmD  
Senior Specialist, Global Medical Information  
Oncology Global Medical Affairs, Merck, Class of 2021

Jena Patel, PharmD  
Senior Specialist, Global Medical Information  
Oncology Global Medical Affairs, Merck, Class of 2021
“As a post-doctoral fellow with Merck, I was provided the opportunity to work with many talented and innovative mentors. The support of my mentors has allowed me to develop the skills needed to be a successful professional in my area. Additionally, the Rutgers component of the fellowship program allowed me to expand upon my leadership capacities and helped further develop me as a professional.”

Rupal Shah, PharmD
RPIF Class of 2009
Global Regulatory Affairs

“Completing a 2-year Regulatory Affairs Fellowship established a strong foundation for my career. My experiences opened my eyes to the many challenges in drug development and the unique opportunities for pharmacists to be able to contribute to the pharmaceutical industry.”

Rupal Shah, PharmD
RPIF Class of 2009
Global Regulatory Affairs

“The Post-Doctoral Fellowship Program at Merck provided me with the tools and skills needed to jump-start my career in the pharmaceutical industry. The challenging and rewarding experiences accelerated my professional development.”

Mujtaba Shahsamand, PharmD
RPIF Class of 2014
Clinical Safety & Risk Management

“The fellowship program provides a great opportunity for PharmD graduates to gain experience and begin their careers in the pharmaceutical industry. As a fellow, I was exposed to many challenging experiences, allowing me to gain the skills needed to become a successful professional.”

Solomon Hassanzadeh, PharmD
RPIF Class of 2017
Clinical Safety & Risk Management
RUTGERS COMPONENT
PROGRAM HISTORY

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 21 companies within the pharmaceutical and biopharmaceutical industry and approximately 300 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the **Institute for Pharmaceutical Industry Fellowships** to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Provide leadership and administrative support;
- Promote quality, communication, and scholarly activity; and
- Arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows’ training by adding select physician fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as Director Emeritus.

More than 1,300 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow’s functional area(s). Our goal is to provide the environment for Fellows to build the foundations for their careers as future leaders in the industry.
ABOUT THE PROGRAM

RUTGERS AND THE ERNEST MARIO SCHOOL OF PHARMACY
Rutgers, The State University of New Jersey, with over 71,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is part of Rutgers Biomedical and Health Sciences, the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its relationship with and, for most, close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

PROFESSIONAL DEVELOPMENT SERIES
All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows’ leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.
Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through the following key program features:

**Family of Leading Companies**
Partners include several of the top global pharmaceutical and biopharmaceutical companies.

**Outstanding Alumni Track Record**
Over 1,300 alumni hold prominent positions at many leading companies.

**Strong Network**
Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and faculty.

**Trusted and Proven Since 1984**
The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.

**Enhanced Career Development**
Breadth of experiences informs career path choices and increasingly challenging assignments build depth of experience, enhancing the potential for accelerated career paths.

**Rigorous Academic Component**
Rutgers affiliation provides academic and professional development opportunities.
Application Process and Eligibility Requirements:
Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

How to Apply:
Interviewing is conducted on a rolling basis. Interested candidates may submit their application and supporting materials (letter of intent, curriculum vitae, and three letters of recommendation) during October 2021 by visiting our website at: pharmafellows.rutgers.edu

All application materials must be submitted electronically to the RPIF Website.

<table>
<thead>
<tr>
<th>Required Items</th>
<th>Deadline*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Intent (LOI)</td>
<td>November 1st</td>
</tr>
<tr>
<td>Curriculum Vitae (CV)</td>
<td>November 1st</td>
</tr>
<tr>
<td>Three Letters of Recommendation (LORs)</td>
<td>December 5th</td>
</tr>
</tbody>
</table>

*Candidates are considered on a rolling basis. Submission of materials prior to deadline is strongly encouraged.

Your Letter of Intent and Letters of Recommendation should be addressed to:
Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020
The trademarks indicated by CAPITAL LETTERS in this publication are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies, except as noted. As used in this publication, the terms “Merck” and the “Company” refer collectively to Merck & Co., Inc., the publicly held parent company, and its domestic and international subsidiaries, which are engaged in the discovery, development, manufacturing and marketing of pharmaceutical and animal health products.